What is Kaleido?
Kaleido is at the forefront of developing innovative, personalized insulin pump systems designed to enhance the quality of life for individuals managing diabetes. The company's technology empowers users to live with greater freedom and confidence by offering advanced, yet user-friendly, solutions. This focus on patient empowerment and technological sophistication positions Kaleido as a key player in the competitive medical device market, particularly within the diabetes care sector.
How much funding has Kaleido raised?
Kaleido has raised a total of $108.9M across 2 funding rounds:
Series B
$10.9M
Series D
$98M
Series B (2016): $10.9M, investors not publicly disclosed
Series D (2026): $98M led by ROM Utrecht Region, Venturing, and Innovation Industries
Key Investors in Kaleido
ROM Utrecht Region
ROM Utrecht Region provides support for innovative entrepreneurs in the Utrecht region, offering assistance with financing, innovation, and international market entry. The company focuses on collaboration within key ecosystems, including Life Sciences Health, Earth Valley, and New Digital Society, to foster project development and growth. They aim to help businesses overcome barriers to international expansion by leveraging their extensive network.
Venturing
We Are Venturing offers comprehensive support to both starting and growing companies, particularly in the technological and marketing sectors. They provide a robust infrastructure of knowledge and resources, including marketing, financial, legal, and human resource support, to help clients achieve their growth targets. The company focuses on enabling partnerships between healthcare, tech, and marketing sectors to foster impactful new technologies and health systems.
Innovation Industries
Innovation Industries is a European venture capital fund that specializes in investing in impactful deep tech companies focused on sustainability and scalability. The firm targets groundbreaking technologies that address significant global challenges, providing support to help these companies maximize their environmental, social, and economic impact.
What's next for Kaleido?
The recent major strategic investment signals Kaleido's transition into a scaling phase, likely focusing on expanding its market reach, further research and development, and enhancing its manufacturing capabilities. With a substantial total funding amount of $108.9M, the company is well-positioned to pursue aggressive growth strategies. Future developments may include broader clinical adoption of its personalized insulin pump systems and potential international market expansion, driven by the strategic backing from its investors.
See full Kaleido company page
